Pathophysiology, Genetics & Classification

Question	Answer
1. What is the fundamental immunologic shift that separates systemic JIA from other JIA categories?	sJIA is classified today as an autoinflammatory disorder driven primarily by innate immunity and pro-inflammatory cytokines (IL-1, IL-6, IL-18), rather than an autoimmune T-cell-mediated condition.
2. Which two primary cytokines act as the key systemic drivers in the pathophysiology of sJIA?	Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6) are the master cytokines responsible for both the systemic features (fever, acute-phase response) and joint pathology.
3. How does the ILAR classification define the fever requirement for diagnosing Systemic JIA?	Documented quotidian fever of at least 2 weeks duration, occurring daily or twice daily, with rapid return to normal or subnormal baseline temperatures.
4. What are the four obligatory non-articular manifestations required alongside fever and arthritis under ILAR criteria?	1. Evanescent salmon-pink rash, 2. Generalized lymphadenopathy (≥ 2 sites), 3. Hepatomegaly and/or splenomegaly, 4. Serositis (pericarditis, pleuritis, or peritonitis).
5. What characteristic skin finding, triggered by minor friction or scratching, is virtually unique to sJIA?	The Koebner phenomenon, where light scratching or pressure from clothing elicits linear streaks of the evanescent salmon-pink macular rash.
6. VIVA TRAP: Can you diagnose Systemic JIA without the presence of active arthritis at initial presentation?	NO. Under ILAR criteria, the presence of arthritis (in ≥ 1 joint) is an absolute mandatory inclusion criterion, even if systemic features appear weeks or months prior.
7. What genetic associations and human leukocyte antigen (HLA) alleles are classically linked to sJIA susceptibility?	Unlike oligoarticular or polyarticular JIA (which are strongly linked to HLA-DRB1), sJIA shows strong associations with polymorphisms in the gene promoter region of IL-6 and macrophage migration inhibitory factor (MIF).
8. What cellular pathway is hyperactivated in Macrophage Activation Syndrome (MAS) complicating sJIA?	Uncontrolled clonal proliferation and activation of CD8+ T-lymphocytes and hemophagocytic macrophages driven by a massive surge of Interferon-gamma (IFN-γ).
9. What is the paradoxical behavior of the Erythrocyte Sedimentation Rate (ESR) during the onset of MAS?	The ESR drops precipitously (falsely normalizing or falling low) due to severe hepatic dysfunction and consumptive hypofibrinogenemia, even as the child clinically deteriorates.
10. What threshold serum ferritin level is classically cited as highly suspicious for impending or active MAS in sJIA?	Serum ferritin levels skyrocketing above 5000 ng/mL (often exceeding 10,000 ng/mL).
11. Name four essential laboratory parameters required to diagnose MAS in the context of sJIA.	1. Thrombocytopenia (<100,000/µL), 2. Hypofibrinogenemia (<150 mg/dL), 3. Hypertriglyceridemia (>156 mg/dL), 4. Hyperferritinemia (>684 ng/mL).
12. What anatomical joint is most frequently involved chronically, leading to severe micrognathia and cervical spine fusion in sJIA?	The temporomandibular joint (TMJ) and cervical spine facets, leading to mandibular growth arrest and micrognathia.
13. Why is sJIA sometimes categorized under autoinflammatory syndromes rather than classical autoimmune arthritis?	Because neutrophils, monocytes, and innate immune pathways are chronically activated without the primary involvement of autoreactive T-cells or high-titer autoantibodies (ANA/RF are typically negative).
14. What role does Interleukin-18 (IL-18) play in the pathogenesis and disease monitoring of sJIA?	Serum IL-18 levels are profoundly elevated in sJIA and remain persistently high during quiescent phases, serving as a powerful biomarker particularly predictive of impending MAS development.
15. What are the key exclusion criteria in the ILAR classification for Systemic JIA?	1. Psoriasis in the patient or first-degree relative, 2. HLA-B27 positive arthritis in a male >6 years, 3. Ankylosing spondylitis or enthesitis-related arthritis, 4. Presence of systemic vasculitis.
16. How does the fever curve of sJIA differ from typical infectious or septic fevers?	The quotidian fever spikes 1–2 times daily to 103-104°F with the child appearing toxic, but during defervescence, temperature completely normalizes and the child remarkably sits up, smiles, and plays.
17. VIVA TRAP: Are Antinuclear Antibodies (ANA) and Rheumatoid Factor (RF) typically positive in typical systemic JIA at onset?	NO. sJIA is characteristically seronegative for both ANA and RF; positivity should prompt re-evaluating the diagnosis toward pSLE or polyarticular JIA.
18. What hematological abnormality is characteristically seen in the complete blood count of a child with active untreated sJIA?	Markedly elevated leukocytosis (often with white cell counts exceeding 20,000 to 30,000/µL with prominent neutrophilia) and severe thrombocytosis.
19. What pathological hepatic change accounts for the hypofibrinogenemia and coagulopathy observed during MAS?	Severe hepatocellular dysfunction coupled with widespread intravascular consumption of coagulation factors by activated hemophagocytic macrophages in the reticuloendothelial system.
20. What is the fundamental rationale for utilizing biologic agents targeting IL-1 and IL-6 as first-line modern therapy in sJIA?	Blocking the master cytokines (IL-1β and IL-6) directly halts the severe systemic inflammatory cascade and prevents refractory joint destruction and life-threatening MAS.

Clinical History & Bedside Evaluation

Question	Answer
1. What is the classic chronological age peak for the presentation of systemic Juvenile Idiopathic Arthritis (sJIA)?	Systemic JIA can present at any age from infancy to adolescence, but it displays no distinct female preponderance (unlike other JIA subtypes) and affects boys and girls equally across early childhood.
2. How does the classic quotidian fever pattern of sJIA help differentiate it clinically from enteric fever or malaria during bedside history taking?	In sJIA, temperature spikes occur once or twice daily with abrupt returns to baseline or subnormal levels, during which the child paradoxically remains playful and interactive, unlike the sustained exhaustion seen in chronic infections.
3. What specific historical detail regarding the evanescent salmon-pink rash must be specifically elicited to confirm its fleeting nature?	The examiner must ask if the rash completely vanishes within hours, particularly correlating its appearance exclusively with the peak of the evening fever spike and fading entirely as defervescence occurs.
4. What historical bedside phenomenon is demonstrated when light scratching or friction from clothing elicits linear streaks of the salmon-pink rash?	This is the Koebner phenomenon (or isomorphic response), a characteristic physical and historical clue elicited during the examination of sJIA skin lesions.
5. How do you quantify morning stiffness clinically during the history taking of a 6-year-old child suspected of having sJIA?	Ask the parents how long the child limps, refuses to walk, or remains irritable upon waking, which in sJIA characteristically lasts for 45 minutes to over an hour.
6. What dietary and nutritional recall is essential when evaluating a child with sJIA presenting with progressive weight loss and abdominal fullness?	Assess total caloric intake, protein-energy adequacy, and appetite loss (anorexia), which are profound due to high circulating levels of inflammatory cytokines like IL-6 and TNF-alpha.
7. Which vital perinatal and developmental historical milestones should be reviewed to rule out primary congenital immunodeficiencies or early-onset autoinflammatory bone disorders?	A detailed birth history, developmental milestones, and history of recurrent neonatal infections must be obtained to rule out monogenic periodic fever syndromes (like MVK deficiency or TRAPS) that mimic sJIA.
8. VIVA TRAP: Can the presence of a purely quotidian fever and generalized lymphadenopathy alone satisfy the ILAR criteria for Systemic JIA without joint involvement?	NO. Under ILAR criteria, confirmed arthritis in at least one joint is an absolute prerequisite, alongside the quotidian fever, before systemic manifestations can be used to diagnose sJIA.
9. What red flag symptoms in the history suggest that an sJIA patient is transitioning from active systemic inflammation into life-threatening Macrophage Activation Syndrome (MAS)?	Rapid neurological deterioration (irritability, lethargy, or seizures), persistent paradoxical absence of joint pain, sudden cessation of fever spikes with rapid drop in ESR, and unexplained bleeding manifestations.
10. What specific gastrointestinal and bleeding symptoms must be actively questioned at the bedside when evaluating a child with suspected MAS?	Inquire about abdominal pain, nausea, mucosal bleeding (epistaxis, gingival bleeding), petechiae, and bruising secondary to consumptive coagulopathy and hepatic dysfunction.
11. How does the onset age and joint distribution in sJIA clinically diverge from systemic lupus erythematosus (pSLE)?	While sJIA can present at a very young age with prominent systemic features and large joint involvement, pSLE typically presents in older school-age children or adolescents with predominant small joint polyarthritis and photosensitive malar rashes.
12. What historical drug exposure history must be rigorously checked before attributing persistent transaminitis in a systemic JIA patient solely to systemic involvement or MAS?	A meticulous medication recall regarding recent non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, or biologic agents known to cause drug-induced hepatotoxicity.
13. What pulmonary red flag symptom in the history of an sJIA patient points toward the dangerous complication of pulmonary alveolar proteinosis or ILD associated with sJIA?	Progressive exertional dyspnea, dry cough, or tachypnea out of proportion to systemic arthritis scores, which carries high mortality in specific sJIA cohorts.
14. What specific inquiry regarding cardiac symptoms must be conducted during bedside evaluation to screen for sJIA-associated serositis?	Ask about retrosternal chest pain, discomfort worsening when lying flat (orthopnea), or dyspnea, which indicate pericarditis—a common visceral manifestation in sJIA.
15. Why is a meticulous vaccination history critical during the initial baseline clinical evaluation of a newly suspected sJIA patient?	Because disease-modifying antirheumatic drugs (DMARDs) and biologic agents (IL-1/IL-6 inhibitors) will soon be initiated, necessitating the completion of live-attenuated vaccines prior to immunosuppression.
16. What historical feature regarding hepatosplenomegaly distinguishes sJIA from infectious mononucleosis or acute leukemias during initial differential workup?	While massive hepatosplenomegaly and lymphadenopathy can mimic hematological malignancy, the daily spiking quotidian fever and evanescent salmon-pink rash strongly point toward sJIA.
17. VIVA TRAP: Is a history of high-dose antibiotic unresponsiveness a reliable diagnostic criterion for establishing the infectious-mimic fever of sJIA?	NO. Unresponsiveness to broad-spectrum antibiotics is merely a clinical observation that prompts a rheumatological evaluation; it does not constitute a formal diagnostic criterion.
18. What specific pain characteristic during night hours (nocturnal bone pain) must be actively screened out to rule out acute leukemia before labeling joint pain as sJIA?	Inquire if pain wakes the child up from deep sleep in the middle of the night and persists independent of movement, which is classically more suggestive of bone marrow malignancy than inflammatory arthritis stiffness.
19. What critical historical detail regarding previous joint involvement patterns helps differentiate sJIA from acute rheumatic fever (ARF)?	Unlike the classically migratory polyarthritis of ARF that resolves completely in one joint as it moves to another, sJIA typically exhibits an additive or persistent polyarticular pattern with prolonged morning stiffness.

Physical Examination & Bedside Signs

Question	Answer
1. What is the classic bedside appearance and general demeanor of a child with sJIA during a quotidian fever spike compared to the afebrile intercritical period?	During a fever spike, the child appears intensely toxic, prostrated, and irritable, whereas during defervescence between spikes, the child remarkably sits up, smiles, and plays normally.
2. How would you inspect and characterize the classic evanescent rash of sJIA on physical examination?	It presents as non-pruritic, salmon-pink macular or maculopapular lesions measuring 2 to 5 mm, predominantly distributed over the trunk, axillae, and proximal thighs.
3. How is the Koebner phenomenon elicited at the bedside in a patient suspected of having sJIA?	By lightly scratching or stroking the skin with a tongue depressor or finger, which elicits linear streaks of the evanescent salmon-pink rash along the path of friction.
4. What specific bedside inspection technique confirms that the sJIA rash is truly evanescent and non-fixed?	Serial inspection reveals that individual lesions last only a few hours, fading completely as the temperature normalizes and reappearing with subsequent fever spikes.
5. What physical signs do you look for during the inspection of the hands and face to detect chronic joint sequelae of long-standing sJIA?	Inspection may reveal micrognathia (bird-like facies) due to early temporomandibular joint involvement, alongside wrist swelling and hand deformities.
6. How do you perform a bedside assessment of joint involvement in the knees for a child with suspected sJIA?	Inspect for joint contour blunting and quadriceps wasting, then palpate for joint line tenderness, local warmth, and elicit the patellar tap or ballotment sign to confirm joint effusion.
7. What bedside maneuver is used to examine cervical spine mobility restricted by early arthritis in sJIA?	Test active and passive range of motion, specifically noting limitation and pain during neck flexion, extension, and lateral rotation caused by cervical facet joint involvement.
8. What specific abdominal examination findings are expected when inspecting and palpating a patient with active systemic JIA?	Inspection may show progressive abdominal fullness, while deep palpation reveals smooth, non-tender hepatomegaly and/or splenomegaly reflecting reticuloendothelial hyperplasia.
9. What auscultatory chest sign must be actively sought during physical examination to detect serositis in a child with sJIA?	A pericardial friction rub heard best along the left sternal border, or diminished breath sounds and a pleural friction rub indicating associated pleuritis.
10. What vital sign changes during the afebrile interval should alert the examiner to impending cardiac tamponade from sJIA-associated pericarditis?	Persistent tachycardia out of proportion to body temperature and pulsus paradoxus (an inspiratory drop in systolic blood pressure >10 mmHg).
11. What anthropometric finding is classically observed on growth charts during physical examination of a child with chronic active sJIA?	Growth failure and linear growth retardation (stunting) resulting from chronic systemic inflammation and prolonged corticosteroid therapy.
12. What specific peripheral lymph node examination finding satisfies the ILAR criteria for generalized lymphadenopathy in sJIA?	Palpation of significant enlargement involving two or more non-contiguous anatomical lymph node groups (e.g., cervical and axillary).
13. What bedside musculoskeletal test is used to assess morning stiffness duration in a young child with sJIA?	Observe the child's spontaneous play and mobility upon waking, noting the time interval required for the child to walk without a limp or stiffness (often lasting ≥ 45 minutes).
14. VIVA TRAP: Can a normal peripheral joint examination rule out systemic JIA entirely during the first week of spiking quotidian fevers?	NO. Arthritis may appear weeks or even months after the onset of quotidian fever; initial presentation may feature only fever, rash, and hepatosplenomegaly.
15. What physical signs on skin and mucosal examination would suggest the development of Macrophage Activation Syndrome (MAS) in sJIA?	The appearance of a non-blanching purpuric rash, petechiae, ecchymoses, or mucosal bleeding manifestations due to consumptive coagulopathy and severe thrombocytopenia.
16. How do you examine and grade active synovitis in the ankles and small joints of the feet during bedside evaluation?	Palpate the periarticular soft tissues for boggy swelling, tenderness to pressure along the joint lines, and reduced range of dorsiflexion and plantarflexion.
17. What bedside respiratory examination sign should be evaluated to screen for sJIA-associated pulmonary alveolar proteinosis or interstitial lung disease?	Bilateral fine end-inspiratory crackles (velcro rales) and tachypnea disproportionate to the degree of active arthritis.
18. What physical examination maneuver is utilized to assess for hip joint arthritis, a frequently overlooked site in sJIA?	Perform the Faber test (Flexion, Abduction, and External Rotation) and check for limitation of internal rotation of the hip accompanied by groin pain.

Diagnostic Criteria & Investigations

Question	Answer
1. What is the pathognomonic hematological profile of active systemic JIA regarding total leukocyte count and platelet count?	Active sJIA characteristically presents with marked leukocytosis (frequently ranging from 15,000 to over 30,000/µL, predominantly neutrophilic) and marked thrombocytosis, reflecting an intense systemic IL-6 driven acute phase response.
2. What quantitative serum ferritin cutoff is generally utilized alongside clinical parameters to suspect the onset of Macrophage Activation Syndrome (MAS) in sJIA?	A serum ferritin level exceeding 684 ng/mL has high sensitivity, but in active clinical practice and sJIA-associated MAS, levels typically skyrocket well above 5,000 to 10,000 ng/mL.
3. VIVA TRAP: Does a normal or moderately elevated erythrocyte sedimentation rate (ESR) rule out severe Macrophage Activation Syndrome in a deteriorating sJIA patient?	NO. A precipitous drop or falsely normal ESR in the face of worsening clinical status is a classic hallmark of MAS, caused by severe hypofibrinogenemia and hepatic synthetic dysfunction.
4. What are the key diagnostic criteria for Macrophage Activation Syndrome complicating systemic JIA according to the 2016 EULAR/ACR classification guidelines?	Classification requires a known or suspected sJIA patient with fever plus a high serum ferritin (>684 ng/mL) along with any two of the following: thrombocytopenia (<181,000/µ L), elevated AST (>48 IU/L), hypertriglyceridemia (>156 mg/dL), or hypofibrinogenemia (<360 mg/dL).
5. What characteristic bone marrow aspirate finding confirms the diagnosis of hemophagocytosis in MAS, and is it mandatory for diagnosis?	Demonstration of macrophages actively phagocytosing hematopoietic cells (erythrocytes, leukocytes, or platelets) confirms MAS, but a negative bone marrow exam does not rule it out if clinical and laboratory criteria are met.
6. Which inflammatory cytokine serves as the primary master regulator and diagnostic biomarker target driving the systemic manifestations of sJIA?	Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6) are the master cytokines; marked elevation of serum IL-18 is also exceptionally characteristic and specific to sJIA.
7. What are the expected cerebrospinal fluid (CSF) findings if central nervous system involvement (CNS-MAS) occurs in sJIA?	CSF analysis may reveal pleocytosis and elevated protein levels (albumin-ocytologic dissociation) in the presence of neurological deterioration.
8. What gold standard radiological imaging modality is used to detect early erosive arthritis and subclinical synovitis in the wrist and small joints of the hand in sJIA?	Contrast-enhanced Magnetic Resonance Imaging (MRI) or high-resolution Musculoskeletal Ultrasound (MSUS) with power Doppler are the gold standards for detecting early synovitis and tenosynovitis long before plain radiographs show changes.
9. What specific early radiological findings are visualized on plain radiographs (X-rays) of the knees and wrists in established systemic JIA?	Initial X-rays typically show soft tissue swelling, juxta-articular osteopenia, and periostitis; later stages reveal joint space narrowing and marginal bony erosions.
10. How does Ultrasound with Power Doppler assist in the diagnostic evaluation of arthritis in sJIA compared to clinical examination?	Power Doppler US provides superior sensitivity over physical exam by detecting active synovial hyperaemia, joint effusion, and synovial hypertrophy even in clinically quiescent or deep joints like the hip.
11. What screening chest imaging is mandatory during the initial diagnostic workup of sJIA to detect baseline serositis or associated interstitial lung disease?	A baseline Chest X-ray (CXR) and, if pulmonary symptoms or digital clubbing are present, a High-Resolution Computed Tomography (HRCT) chest to screen for sJIA-associated lung disease (PAP-like illness).
12. What diagnostic electrocardiogram (ECG) and echocardiographic findings are anticipated when serositis involves the pericardium in sJIA?	ECG may show low-voltage QRS complexes and diffuse PR segment depression, while Echocardiography demonstrates pericardial effusion, fibrinous strands, or varying degrees of myocardial dysfunction.
13. What standard liver function test abnormalities are frequently observed during active systemic sJIA flares even prior to any hepatotoxic drug exposure?	Mild-to-moderate transaminitis (elevated AST and ALT) and elevated alkaline phosphatase can occur as part of systemic reticuloendothelial activation, though severe elevations demand immediate rule-out of MAS or drug-induced injury.
14. What specific renal function and urinalysis parameters are monitored during the diagnostic evaluation and management of sJIA?	Serum creatinine, estimated GFR, and routine urinalysis (checking for proteinuria and microscopic hematuria) are essential to monitor for secondary AA amyloidosis or renal involvement from macrophage activation syndrome.
15. What diagnostic blood test is used to rule out Autoimmune Hemolytic Anemia or primary hematological malignancies when a child presents with cytopenias and hepatosplenomegaly?	A direct Coombs test (DCT) alongside peripheral blood smear examination for atypical cells, blasts, or schistocytes is mandatory to rule out leukemia and autoimmune cytopenias.
16. What specialized radiological evaluation is indicated when a patient with sJIA develops intractable morning stiffness and restricted neck movement?	Cervical spine flexion-extension lateral radiographs or a cervical spine MRI to evaluate for atlantoaxial subluxation or apophyseal joint fusion (though cervical fusion is more typical of systemic-onset or polyarticular subtypes).
17. How are coagulation profiles altered during the progression from active sJIA to full-blown Macrophage Activation Syndrome?	While active sJIA causes a hypercoagulable state with elevated fibrinogen and D-dimer, the development of MAS triggers consumptive coagulopathy characterized by prolonged PT/aPTT, elevated D-dimer, and a profound drop in plasma fibrinogen.
18. What diagnostic value does abdominal imaging (Ultrasonography) hold in a child presenting with sJIA symptoms and abdominal fullness?	Abdominal USG confirms and quantifies hepatomegaly, splenomegaly, and generalized lymphadenopathy, while ruling out other intra-abdominal pathologies or surgical emergencies.
19. What specific autoantibody panel is essential to order when differentiating systemic JIA with arthritis and rash from pediatric Systemic Lupus Erythematosus (pSLE)?	Anti-Double Stranded DNA (anti-dsDNA) and Anti-Nuclear Antibody (ANA) titers, which are characteristically positive in pSLE but negative or low-titer in uncomplicated sJIA.

Evidence-Based Management & Pharmacotherapy

Question	Answer
1. What is the initial stepwise pharmacological management for a child presenting with mild systemic JIA without systemic toxicity or active organ-threatening manifestations?	1. High-dose non-steroidal anti-inflammatory drugs (NSAIDs) such as Naproxen (15-20 mg/kg/day in 2 divided doses) or Indomethacin (2-3 mg/kg/day). 2. NSAIDs are primarily effective for fever and mild arthritis but rarely control the full systemic disease long-term.
2. What is the standard oral corticosteroid dosing regimen and preferred route for moderate-to-severe systemic JIA unresponsive to initial NSAID therapy?	1. Oral Prednisolone initiated at 1-2 mg/kg/day (maximum 60 mg/day) divided or as a single daily dose. 2. Tapering is initiated very slowly only after complete normalization of systemic symptoms, inflammatory markers, and fever for at least 4 to 6 weeks.
3. What is the exact dosing schedule and administration protocol for intravenous methylprednisolone pulse therapy in severe or life-threatening systemic JIA flares?	1. IV Methylprednisolone pulse at 30 mg/kg/dose (maximum 1000 mg/dose) administered once daily for 3 consecutive days. 2. Infused slowly over at least 1 to 2 hours with continuous cardiac and blood pressure monitoring.
4. What is the exact therapeutic dosage and mechanism of action of Anakinra when utilized as first-line biologic therapy in systemic JIA?	1. Anakinra is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra), blocking both IL-1alpha and IL-1beta signaling. 2. Administered subcutaneously at a dose of 1-2 mg/kg/day (can be escalated up to 4 mg/kg/day or higher in refractory disease or MAS).
5. What is the weight-based dosing and administration frequency of Canakinumab, the long-acting monoclonal antibody targeting IL-1beta in systemic JIA?	1. Canakinumab is dosed at 4 mg/kg (maximum 150 mg) administered via subcutaneous injection strictly once every 4 weeks. 2. It offers the advantage of extended dosing intervals compared to daily Anakinra while effectively controlling both articular and systemic features.
6. What is the mechanism of action, route, and dosage of Tocilizumab in the management of refractory systemic JIA?	1. Tocilizumab is a humanized monoclonal antibody directed against the soluble and membrane-bound Interleukin-6 receptor (IL-6R). 2. Administered intravenously every 2 weeks at a dose of 8 mg/kg for patients weighing ≥ 30 kg, and 12 mg/kg for patients <30 kg.
7. What specific baseline screening investigations are mandatory prior to initiating biologic DMARD therapy like Anakinra, Canakinumab, or Tocilizumab?	1. Screening for latent and active tuberculosis using a Tuberculin Skin Test (TST) or Interferon-Gamma Release Assay (IGRA). 2. Baseline viral serology including Hepatitis B surface antigen, Hepatitis C antibody, and HIV, alongside a complete blood count and liver function tests.
8. What is the therapeutic approach and emergency pharmacological regimen for treating Macrophage Activation Syndrome (MAS) secondary to systemic JIA?	1. Immediate high-dose IV methylprednisolone pulses (30 mg/kg/day) combined with high-dose Anakinra (2-4 mg/kg every 6 to 12 hours subcutaneously). 2. In refractory or life-threatening cases, cyclosporine A (2-7 mg/kg/day orally or IV) or etoposide is added to control the cytokine storm.
9. What mandatory clinical and laboratory monitoring is required for a patient receiving chronic high-dose systemic corticosteroid therapy for sJIA?	1. Regular monitoring of blood pressure, blood glucose (fasting and postprandial), and routine urinalysis for glycosuria. 2. Stool occult blood testing, regular monitoring of height and weight trajectories for growth failure, and periodic bone mineral density assessment or dual-energy X-ray absorptiometry (DEXA) for osteoporosis.
10. VIVA TRAP: Can non-steroidal anti-inflammatory drugs (NSAIDs) be continued indefinitely as monotherapy in children with systemic JIA once systemic symptoms improve?	NO. NSAIDs are inadequate as long-term monotherapy for systemic JIA because they do not alter the underlying immunologic disease progression, prevent joint erosions, or adequately suppress chronic systemic inflammation.
11. What is the recommended management strategy for severe, refractory macrophage activation syndrome (MAS) that fails to respond to high-dose corticosteroids and Anakinra?	1. Administration of Cyclosporine A intravenously (starting at 2-3 mg/kg/day, titrated to blood levels) or biological agents like anti-interferon-gamma (emapalumab) or IVIG. 2. In extreme, unremitting refractory cytopenias and multi-organ failure, protocol-driven hemophagocytic lymphohistiocytosis (HLH) chemotherapy regimens containing Etoposide are considered.
12. What adjunctive pharmacological prophylaxis must be prescribed routinely to any pediatric patient initiated on high-dose systemic corticosteroids and methotrexate?	1. Daily oral calcium and Vitamin D supplementation to prevent corticosteroid-induced osteoporosis. 2. Weekly oral folic acid supplementation (at least 1 mg daily except on the day of methotrexate) to minimize methotrexate toxicity and mucositis.
13. What specific vaccination precautions must be enforced in children with systemic JIA who are established on biologic DMARDs and immunosuppressive agents?	1. Administration of live-attenuated vaccines (such as MMR, Varicella, Oral Polio, BCG, Rotavirus) is strictly CONTRAINDICATED while on biologic DMARDs and high-dose immunosuppression. 2. Inactivated vaccines (such as Influenza, Pneumococcal, Inactivated Polio, and COVID-19) are recommended but should be administered during periods of lower disease activity and optimal spacing from biologic infusions.
14. What specialized surgical intervention or orthopedic procedure is occasionally indicated in patients with longstanding, end-stage destructive hip or knee joint arthritis from sJIA?	1. Total Joint Arthroplasty (Hip or Knee Replacement surgery) to restore mobility, correct fixed flexion deformities, and alleviate intractable pain. 2. Performed strictly after achieving prolonged, sustained clinical remission of systemic inflammation and under carefully managed biologic/immunosuppressive withdrawal protocols.
15. VIVA TRAP: Is Anakinra administration completely safe from local adverse effects when given via subcutaneous injection daily?	NO. Anakinra frequently causes prominent, painful, pruritic erythematous injection site reactions (ISRs), which typically occur within the first few weeks of therapy and usually resolve spontaneously without necessitating drug discontinuation.
16. What long-term surveillance and monitoring schedule is mandated for pediatric patients with systemic JIA who have achieved clinical remission off all medications?	1. Regular periodic follow-ups with pediatric rheumatology every 3 to 6 months for clinical evaluation of subtle joint contractures, growth velocity, and functional capacity. 2. Serial monitoring of acute phase reactants (ESR and CRP) and periodic surveillance for secondary amyloidosis (evaluating serum creatinine and spot urine protein-to-creatinine ratio).
17. What specific structural and functional rehabilitation modalities form an essential pillar of evidence-based management alongside pharmacotherapy in systemic JIA?	1. Supervised physical therapy focusing on daily range-of-motion exercises, muscle strengthening, and hydrotherapy to prevent joint contractures and muscle atrophy. 2. Occupational therapy and splinting (especially night resting splints for wrists and knees) to prevent the development of fixed deformities during acute inflammatory flares.

High-Yield VIVA TRAPs & Examiner Pitfalls

Question	Answer
1. VIVA TRAP: Can a definitive diagnosis of systemic JIA be made if the patient has had a quotidian fever for only 5 days alongside classic salmon-pink rash and polyarthritis?	NO. The ILAR criteria strictly mandate that the documented quotidian fever must be of at least 2 weeks duration before systemic JIA can be formally diagnosed.
2. VIVA TRAP: Is the salmon-pink evanescent rash of systemic JIA intensely pruritic, and does it leave hyperpigmentation or scaling upon fading?	NEVER. The sJIA rash is characteristically non-pruritic, fleeting (evanescent), and disappears completely without leaving any residual scaling, scarring, or hyperpigmentation.
3. VIVA TRAP: Can an examiner accept a history of a fixed erythematous facial malar rash as a diagnostic feature of uncomplicated systemic JIA?	NO. A fixed malar or butterfly rash strongly points toward pediatric Systemic Lupus Erythematosus (pSLE), whereas sJIA features a fleeting, evanescent truncal rash that coincides strictly with fever spikes.
4. VIVA TRAP: Are serum Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies characteristically positive in children with active systemic JIA?	NONE. Systemic JIA is fundamentally an auto-inflammatory disorder driven by innate immunity, and both RF and anti-CCP are characteristically negative (seronegative).
5. VIVA TRAP: Should methotrexate be chosen as the primary initial monotherapy to induce rapid remission in a severely toxic child presenting with acute systemic JIA and generalized serositis?	NEVER. Methotrexate is a slow-acting conventional DMARD requiring weeks to take effect and is utterly inadequate for life-threatening acute systemic or organ-threatening sJIA flares, which demand systemic corticosteroids or targeted biologics.
6. VIVA TRAP: Is it acceptable to administer live attenuated vaccines (such as MMR or Varicella) to a child currently receiving biologic therapy or high-dose immunosuppression for sJIA?	NEVER. Live attenuated vaccines are strictly contraindicated in immunosuppressed or biologic-treated children due to the grave risk of unhindered, disseminated vaccine-strain infection.
7. VIVA TRAP: Can intra-articular corticosteroid injections be performed safely during an active systemic inflammatory flare with high quotidian fevers and multi-organ involvement?	NO. Intra-articular injections are reserved for persistent oligoarticular flares or localized joint involvement; they hold no therapeutic value for systemic symptoms, fever, or life-threatening organ inflammation.
8. VIVA TRAP: Does the presence of generalized lymphadenopathy and hepatosplenomegaly in sJIA mandate immediate surgical lymph node biopsy or bone marrow trephine to rule out malignancy?	NO. While malignancy (like acute lymphoblastic leukemia) must always be considered in the differential diagnosis, classic sJIA features systemic reticuloendothelial activation that typically responds to targeted anti-inflammatory or biologic therapy without requiring upfront invasive biopsies, provided initial hematological screenings are non-alarming.
9. VIVA TRAP: Can Anakinra treatment be abruptly stopped without tapering or bridging when a patient achieves clinical remission from sJIA?	NO. Abrupt cessation of biologic IL-1 blockade frequently precipitates a severe rebound inflammatory flare of sJIA or triggers secondary Macrophage Activation Syndrome; therapy must be tapered gradually under clinical and laboratory supervision.
10. VIVA TRAP: Is Tocilizumab monotherapy entirely free of the risk of severe infections because it targets IL-6 rather than broad T-cell immunity?	NO. Tocilizumab blockade of IL-6 significantly blunts the acute phase response (masking classic fever and CRP elevation during serious bacterial sepsis) and carries a substantial risk of serious infections and gastrointestinal perforation.
11. VIVA TRAP: Should non-steroidal anti-inflammatory drugs (NSAIDs) be continued at high therapeutic doses in a sJIA patient who develops acute oliguric acute kidney injury and rising transaminases?	NEVER. NSAIDs inhibit renal prostaglandins, compromising renal perfusion and exacerbating hepatic and renal injury, and must be discontinued immediately in the presence of acute kidney injury or severe cytopenias.
12. VIVA TRAP: Is physical therapy and joint mobilization strictly prohibited during the acute painful phase of polyarthritis in sJIA?	NO. Complete joint immobilization leads to rapid muscle atrophy and permanent contractures; gentle passive and active-assisted range of motion exercises must be initiated early alongside anti-inflammatory therapy under expert pediatric rheumatology and physiotherapy guidance.
13. VIVA TRAP: Can Canakinumab be administered on a bi-weekly (every 2 weeks) schedule as standard maintenance dosing for systemic JIA in pediatric practice?	NO. Canakinumab is specifically formulated as a long-acting monoclonal antibody with a standard approved dosing interval of every 4 weeks (4 mg/kg subcutaneously).
14. VIVA TRAP: Is a bone marrow biopsy mandatory to diagnose Macrophage Activation Syndrome (MAS) in every single case of sJIA presenting with clinical deterioration?	NO. Bone marrow examination showing hemophagocytosis is supportive but not strictly mandatory if the patient fulfills validated 2016 EULAR/ACR classification criteria combining clinical and laboratory parameters (hyperferritinemia, cytopenias, hypofibrinogenemia, elevated AST/ALT).
15. VIVA TRAP: Can children with systemic JIA be safely transitioned from parenteral biologic injections to daily oral NSAID monotherapy during mild intercurrent viral upper respiratory infections?	NO. Intercurrent viral infections are well-known triggers for catastrophic sJIA flares or secondary MAS; baseline biologic and immunomodulatory therapy must be managed cautiously under pediatric rheumatology oversight, and NSAIDs alone are entirely insufficient to control systemic disease activity.
16. VIVA TRAP: Is pediatric systemic JIA classified as a purely autoimmune disease driven by antigen-specific T and B lymphocyte clones against self-antigens?	NO. Systemic JIA is fundamentally classified as an autoinflammatory disorder driven primarily by innate immune dysregulation, characterized by massive activation of phagocytes (macrophages and neutrophils) and profound overproduction of interleukin-1 and interleukin-6.